Hepcidin, a Key Regulator of Iron Metabolism, is Transcriptionally Activated by P53
Overview
Authors
Affiliations
Hepcidin is an iron-regulatory protein that is upregulated in response to increased iron or inflammatory stimuli. Hepcidin reduces serum iron and induces iron sequestration in the reticuloendothelial macrophages - the hallmark of anaemia of inflammation. Iron deprivation is used as a defense mechanism against infection, and it also has a beneficial effect on the control of cancer. The tumour-suppressor p53 transcriptionally regulates genes involved in growth arrest, apoptosis and DNA repair, and perturbation of p53 pathways is a hallmark of the majority of human cancers. This study inspected a role of p53 in the transcriptional regulation of hepcidin. Based on preliminary bioinformatics analysis, we identified a putative p53 response-element (p53RE) contained in the hepcidin gene (HAMP) promoter. Chromatin immunoprecipitation (ChIP), reporter assays and a temperature sensitive p53 cell-line system were used to demonstrate p53 binding and activation of the hepcidin promoter. p53 bound to hepcidin p53RE in vivo, andthis p53RE could confer p53-dependent transcriptional activation. Activation of p53 increased hepcidin expression, while silencing of p53 resulted in decreased hepcidin expression in human hepatoma cells. Taken together, these results define HAMP as a novel transcriptional target of p53. We hypothesise that hepcidin upregulation by p53 is part of a defence mechanism against cancer, through iron deprivation. Hepcidin induction by p53 might be involved in the pathogenesis of anaemia accompanying cancer.
Iron metabolism in a mouse model of hepatocellular carcinoma.
Yilmaz D, Tharehalli U, Paganoni R, Knoop P, Gruber A, Chen Y Sci Rep. 2025; 15(1):2180.
PMID: 39820815 PMC: 11739418. DOI: 10.1038/s41598-025-86486-x.
Adegboro A, Afolabi I Front Cell Dev Biol. 2024; 12:1374735.
PMID: 38660623 PMC: 11039840. DOI: 10.3389/fcell.2024.1374735.
HIF2α, Hepcidin and their crosstalk as tumour-promoting signalling.
Formica V, Riondino S, Morelli C, Guerriero S, DAmore F, Di Grazia A Br J Cancer. 2023; 129(2):222-236.
PMID: 37081189 PMC: 10338631. DOI: 10.1038/s41416-023-02266-2.
Targeting iron metabolism in osteosarcoma.
Ma X, Zhao J, Feng H Discov Oncol. 2023; 14(1):31.
PMID: 36897430 PMC: 10006389. DOI: 10.1007/s12672-023-00637-y.
Hepcidin in hepatocellular carcinoma.
Joachim J, Mehta K Br J Cancer. 2022; 127(2):185-192.
PMID: 35264787 PMC: 9296449. DOI: 10.1038/s41416-022-01753-2.